Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Chemical synthesis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    15 result(s) found for: Chemical synthesis. Displaying page 1 of 1.
    EudraCT Number: 2004-001114-14 Sponsor Protocol Number: ST261-DS-02-002 Start Date*: 2004-10-22
    Sponsor Name:SIGMA-TAU
    Full Title: BIOAVAILABILITY AND BIOEQUIVALENCE OF TWO ORAL FORMULATION OF L-PROPIONYLCARNITINE TABLET VS SACHET IN HEALTHY VOLUNTEERS AT THE DOSE OF 2 G OPEN, RANDOMISED, TWO-WAYS CROSS-OVER, SINGLE DOSE STUDY
    Medical condition: BIOEQUIVALENCE /BIOAVAILABILITY STUDY
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-004880-33 Sponsor Protocol Number: 18F-FDOPA-BUP-ESC Start Date*: 2023-01-20
    Sponsor Name:Medical University of Vienna, University Department of Psychiatry and Psychotherapy
    Full Title: Reward-specific changes of cerebral dopamine synthesis in healthy volunteers and depressed patients
    Medical condition: Major Depression
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-004153-24 Sponsor Protocol Number: CRAD001JIT36T Start Date*: 2014-05-25
    Sponsor Name:Dipartimento di Scienze Chirurgiche, Oncologiche e Gastroenterologiche
    Full Title: MAINtenance Afinitor (MAIN-A): A randomized trial comparing maintenance aromatase inhibitors (AIs) + everolimus (Afinitor) vs. AIs in patients withHR+ metastatic breast cancer with disease control ...
    Medical condition: HR+ / HER2 negative metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-001378-97 Sponsor Protocol Number: Ped3CB/P01/06/Mu.B Start Date*: 2007-08-14
    Sponsor Name:Baxter SAS
    Full Title: Safety during use of paediatric triple chamber bag formulas administered IV at a weight dependant dose during 5 consecutive days in paediatric patients up to 18 years requiring parenteral nutrition...
    Medical condition: The study is not focussed on a particular pathology but rather on the use of triple chamber bags in paediatrics, in any pathology requiring parenteral nutrition
    Disease: Version SOC Term Classification Code Term Level
    9.1 10051284 Parenteral nutrition PT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2012-001757-21 Sponsor Protocol Number: ESH-CHL-SHOT Start Date*: 2013-05-21
    Sponsor Name:ISTITUTO AUXOLOGICO ITALIANO
    Full Title: European Society of Hypertension and Chinese Hypertension League stroke in hypertension optimal treatment trial
    Medical condition: Patients with arterial hypertension and previous stroke or transient ischemic attack
    Disease: Version SOC Term Classification Code Term Level
    15.0 10047065 - Vascular disorders 10047065 Vascular disorders SOC
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Completed) SE (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-007932-25 Sponsor Protocol Number: 28091 Start Date*: 2008-05-07
    Sponsor Name:Merck Lipha Santé
    Full Title: A phase IIIb randomized open-label study to compare between IVF/ICSI outcomes two regimen of Cetrotide 0.25 mg used from Day 1 or from Day 7 of the menstrual cycle (Day 0 or Day 6 of stimulation) ...
    Medical condition: Prevention of premature ovulation in polycystic ovarian women undergoing a controlled ovarian stimulation, followed by oocyte pick-up and assisted reproductive techniques.
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2006-005711-10 Sponsor Protocol Number: OX22-006 Start Date*: 2007-02-26
    Sponsor Name:Orexo AB
    Full Title: A double-blind, randomised, two-period crossover study to evaluate the hypnotic effects and safety of sublingual zolpidem for the treatment of insomnia.
    Medical condition: Primary insomnia
    Disease: Version SOC Term Classification Code Term Level
    8.1 10036701 Primary insomnia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2014-002481-78 Sponsor Protocol Number: EBI-EA230-LPS-2014 Start Date*: 2014-10-07
    Sponsor Name:Exponential Biotherapies Inc
    Full Title: Randomized double blind placebo-controlled clinical safety, tolerability and pharmacokinetic/-dynamic study on the effects of escalating single intravenous doses of EA-230 on the innate immune resp...
    Medical condition: Systemic inflammatory respons (SIRS) and associated acute kidney injury (AKI)
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2015-005600-28 Sponsor Protocol Number: EBI-CABG Start Date*: 2016-06-17
    Sponsor Name:Exponential Biotherapies Inc.
    Full Title: Randomized double blind placebo-controlled phase II study on the effects of EA-230 on the innate immune response following on-pump cardiac surgery
    Medical condition: Systemic inflammatory respons (SIRS) and associated acute kidney injury (AKI)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2013-004955-19 Sponsor Protocol Number: PARIDA-01/2013 Start Date*: 2014-09-03
    Sponsor Name:Azienda Ospedaliera di Padova
    Full Title: PARACETAMOL VERSUS IBUPROFEN FOR PATENT DUCTUS ARTERIOSUS TREATMENT IN PRETERM INFANTS.
    Medical condition: patent ductus arteriosus hemodynamically important
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004865 10034190 PDA Repair patent ductus arteriosus LLT
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2004-001927-39 Sponsor Protocol Number: ST1472-DM-03-007 Start Date*: 2005-01-20
    Sponsor Name:SIGMA-TAU
    Full Title: A PHASE II, MULTICENTER, UNCONTROLLED, OPEN STUDY IN PATIENTS WITH CHRONIC HEPATITIS C WHO ARE INTOLERANT TO INTERFERONS THERAPY TO EVALUATE THE SAFETY AND EFFICACY OF A TREATMENT WITH THYMOSIN ALP...
    Medical condition: TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C WHO ARE INTOLERANT TO INTERFERONS THERAPY
    Disease: Version SOC Term Classification Code Term Level
    6.1 10019744 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-005597-43 Sponsor Protocol Number: RG_06-280 Start Date*: 2008-02-04
    Sponsor Name:University of Birmingham [...]
    1. University of Birmingham
    2. Birmingham Heartlands Hospital
    Full Title: Topical Retinoids and Diabetic Neuropathic Ulceration
    Medical condition: The overall goal of the proposal is to assess the capacity of topical retinoid treatment to induce changes in connective tissue metabolism (i.e., increased collagen production and decreased elabora...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050712 Vitamin A LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-003204-40 Sponsor Protocol Number: PATHBP_2013 Start Date*: 2014-01-20
    Sponsor Name:University of Edinburgh [...]
    1. University of Edinburgh
    2. NHS Lothian
    Full Title: Paracetamol treatment in hypertension: effect on blood pressure
    Medical condition: Hypertension
    Disease: Version SOC Term Classification Code Term Level
    14.1 10022891 - Investigations 10005729 Blood pressure ambulatory PT
    14.1 10047065 - Vascular disorders 10020775 Hypertension arterial LLT
    14.1 10022891 - Investigations 10005756 Blood pressure systolic PT
    14.1 10047065 - Vascular disorders 10020772 Hypertension PT
    14.1 10022891 - Investigations 10005735 Blood pressure diastolic PT
    14.1 10022891 - Investigations 10033762 Paracetamol LLT
    14.1 10022891 - Investigations 10005727 Blood pressure PT
    14.1 10047065 - Vascular disorders 10015488 Essential hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-001515-31 Sponsor Protocol Number: NEOMERO-1 Start Date*: 2011-08-25
    Sponsor Name:FONDAZIONE PENTA ONLUS
    Full Title: EFFICACY, PHARMACOKINETICS AND SAFETY OF MEROPENEM IN INFANTS BELOW 90 DAYS OF AGE (INCLUSIVE) WITH CLINICAL OR CONFIRMED LATE-ONSET SEPSIS: A EUROPEAN MULTICENTER RANDOMISED PHASE III TRIAL
    Medical condition: late onset sepsis in the neonate and infant up to 90 days of age
    Disease: Version SOC Term Classification Code Term Level
    17.0 10021881 - Infections and infestations 10053840 Bacterial sepsis PT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: EE (Completed) GR (Completed) LT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2011-001521-25 Sponsor Protocol Number: NEOMERO-2 Start Date*: 2011-12-15
    Sponsor Name:FONDAZIONE PENTA ONLUS
    Full Title: Pharmacokinetics and safety of Meropenem in infants below 90 days of age (inclusive) with probable and confirmed meningitis: a European multicenter phase II trial
    Medical condition: Bacterial meningitis in children up to 90 days of age
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004862 10004049 Bacterial meningitis LLT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: EE (Completed) GR (Completed) LT (Completed) ES (Completed) NL (Completed) GB (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 29 15:31:09 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA